Humacyte shares surge 12.38% after-hours on US DoD funding for Symvess bioengineered blood vessels.

Humacyte Inc. surged 12.38% in after-hours trading following the announcement of significant U.S. Department of Defense funding under the 2026 Appropriations Act to advance its bioengineered blood vessel product, Symvess. The funding, highlighted as a strategic win, reinforced market optimism about the company’s technological potential and government contract opportunities. Analysts cited the development as a catalyst for long-term growth, despite ongoing financial challenges such as negative EBIT margins. The stock’s rise aligns with news of a 28% intraday jump earlier in the day, driven by similar positive sentiment around the FDA breakthrough designation and DoD support. The after-hours rally reflects investor confidence in Humacyte’s ability to leverage the funding for R&D and market expansion in vascular repair technologies.